LPL Financial’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,070
| Closed | -$10.4K | – | 5511 |
|
|
2024
Q3 | $10.4K | Sell |
2,070
-1
| -0% | -$6 | ﹤0.01% | 5126 |
|
|
2024
Q2 | $13.7K | Sell |
2,071
-40
| -2% | -$272 | ﹤0.01% | 4956 |
|
|
2024
Q1 | $23.2K | Buy |
2,111
+39
| +2% | +$422 | ﹤0.01% | 4835 |
|
|
2023
Q4 | $28K | Sell |
2,072
-81
| -4% | -$1.31K | ﹤0.01% | 4708 |
|
|
2023
Q3 | $46.7K | Sell |
2,153
-25
| -1% | -$801 | ﹤0.01% | 4527 |
|
|
2023
Q2 | $83.9K | Buy |
2,178
+106
| +5% | +$3.74K | ﹤0.01% | 4354 |
|
|
2023
Q1 | $57.4K | Buy |
2,072
+1,980
| +2,152% | +$67.1K | ﹤0.01% | 4288 |
|
|
2022
Q4 | $3.03K | Buy |
92
+46
| +100% | +$3.35K | ﹤0.01% | 4446 |
|
|
2022
Q3 | $6K | Hold |
46
| – | – | ﹤0.01% | 4392 |
|
|
2022
Q2 | $8K | Hold |
46
| – | – | ﹤0.01% | 4394 |
|
|
2022
Q1 | $13K | Hold |
46
| – | – | ﹤0.01% | 4148 |
|
|
2021
Q4 | $24K | Buy |
46
+2
| +5% | +$1.44K | ﹤0.01% | 4285 |
|
|
2021
Q3 | $17K | Hold |
44
| – | – | ﹤0.01% | 4292 |
|
|
2021
Q2 | $39K | Buy |
+44
| New | +$33.6K | ﹤0.01% | 4162 |
|
LPL Financial's BIOR Position: Q4 2024 in Review
LPL Financial sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 2,070 shares — an estimated $10.4K sold.
LPL Financial first reported a position in BIOR in Q2 2021 and held it in 14 quarters. The position peaked at $83.9K in Q2 2023. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- LPL Financial reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- LPL Financial sold 2,070 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $10.4K.
- LPL Financial first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
- LPL Financial's Biora Therapeutics, Inc. Common Stock position peaked at $83.9K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on LPL Financial's 13F filing for Q4 2024, filed 11 Feb 2025.